Peptidream

Basic Information

Stock Code
4587
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Kanagawa Prefecture
Establishment Year
July 2006
Listing Year
June 2013
Official Website
https://www.peptidream.com/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNI Group, Heartseed, Ubicom, Sumitomo Pharma, AnGes, NexGen Pharma, SanBio, Helios, Rena Science, QualiPs, Takara Bio, Nomura Micro Science, Japan Tissue Engineering

Overview

Peptidream is a University of Tokyo spin-off bio-venture established in 2006, a leading company aiming to revolutionize drug development armed with a drug discovery platform based on special peptide technology.

Current Situation

As of the end of December 2023, Peptidream operates with a consolidated workforce of 713 employees, posting net sales of approximately 4.9 billion yen and net profit of approximately 1.9 billion yen, maintaining a stable revenue base. As a pioneer in drug discovery research using special peptides, it is generating numerous product candidates in areas such as multiple neurodegenerative diseases and cancer via its PDPS platform leveraging proprietary technologies like Flexizyme, FIT system, and RAPID display. It has established a business model earning upfront contract payments, milestone payments, and royalties through numerous alliance agreements with major pharmaceutical companies worldwide. Since 2017, it has relocated its headquarters and research institute to Kawasaki City, Kanagawa Prefecture, accelerating R&D by utilizing the industry-academia-government collaboration ecosystem. In 2022, it acquired subsidiary PDR Pharma in the radiopharmaceutical field, expanding its business portfolio. Going forward, it will focus on accelerating new drug development and creating high value-added offerings through technology advancement and strengthened global partnerships. It is also advancing sustainability measures at its drug substance production sites from environmental and social perspectives, aiming to enhance long-term corporate value.

Trivia

Interesting Facts

  • Gaining attention as a University of Tokyo spin-off bio-venture
  • Flexizyme technology patented worldwide
  • Capable of synthesizing hundreds of billions of special peptides in a test tube
  • Received Industry-Academia-Government Collaboration Merit Award in 2011
  • Full-scale entry into radiopharmaceuticals for business expansion
  • Consolidated research bases in Kawasaki Kingskyfront
  • Concluded joint development contracts with many major pharma companies
  • Strengthened manufacturing via PDR Pharma subsidiary
  • Founder Hiromi Suga is University of Tokyo professor and inventor
  • PDPS platform achieves diversity and speed
  • Special peptides positioned as third modality in pharmaceuticals
  • Traded at 3.2 times issue price on IPO debut day
  • Broad application range of proprietary technology across many diseases
  • RAPID Display is high-speed screening technology
  • Sustained growth after contract terminations with multinational pharmas

Hidden Connections

  • Contributes to advanced medical industry cluster in Kawasaki area via lab relocation
  • Bridges pharma and chemicals via JV with Sekisui Chemical
  • Strengthened Fujifilm collaboration through radiopharmaceutical business inheritance
  • Strong ties with multinationals like AstraZeneca
  • Founded with investment from University of Tokyo venture capital
  • Industry-Academia-Government Collaboration Merit Award is honor from Japan Academy President
  • Significantly reduced imitation risk through patent protection of technology
  • Growth company that moved from Tokyo Mothers to Tokyo 1st Section

Future Outlook

Growth Drivers

  • Improved drug discovery success probability via proprietary technology
  • Strengthened partnerships with major domestic and international pharmas
  • Expansion of radiopharmaceutical market
  • Broader applicability from biotechnology advances
  • Faster and more efficient drug discovery screening technology
  • Accelerated R&D through industry-academia-government collaboration
  • Global increase in biopharmaceutical demand
  • Maintained competitive edge through patent protection
  • Diversification of societal medical needs
  • Expanded applicability in regenerative medicine
  • Increased diagnostic and therapeutic uses for radiopharmaceuticals
  • Accelerated next-gen pharmaceutical development

Strategic Goals

  • Global expansion of PDPS platform
  • Achieve net sales over 10 billion yen
  • Launch numerous new drug candidates
  • Establish and strengthen sustainability management reporting
  • Build sustainable manufacturing systems
  • Expand radiopharmaceutical market share
  • Robustify intellectual property via international patents
  • Improve employee diversity and work-life balance
  • Expand patient contributions through innovative pharmaceuticals
  • Become leading company in industry-academia collaboration model

Business Segments

Drug Discovery Platform Provision

Overview
Provides platform services supporting drug candidate creation using proprietary technologies.
Competitiveness
Differentiated by patented diverse peptide creation technologies.
Customers
  • Major Pharmaceutical Companies
  • Bio-Ventures
  • Research Universities
  • Medical Institution Research Departments
  • Chemical Manufacturers
  • Industry-Academia-Government Collaboration Groups
Products
  • Special Peptide Libraries
  • FIT System Applied Technology
  • RAPID Display Screening
  • Flexizyme Technology Provision
  • Drug Discovery Consulting
  • IP Sharing Programs

Special Peptide API Manufacturing & Supply

Overview
Manufactures and supplies high-quality special peptide pharmaceutical APIs in collaboration with joint venture Peptistar.
Competitiveness
Advanced manufacturing technology and quality control systems as strengths.
Customers
  • Pharmaceutical Companies
  • Contract Manufacturers
  • Bio-Pharmaceutical Developers
  • Drug Discovery Partners
Products
  • Special Peptide APIs
  • Radiopharmaceutical APIs
  • Antibody-Conjugated Peptides
  • Molecular Targeted Peptide APIs

Radiopharmaceutical Business

Overview
Inherited business from Fujifilm Toyama Chemical to research, develop, and manufacture radiopharmaceuticals for cancer diagnosis and treatment.
Competitiveness
One-stop provision from development to manufacturing of radiopharmaceuticals.
Customers
  • Hospitals
  • Diagnostic Drug Manufacturers
  • Pharmaceutical Companies
  • Research Institutions
Products
  • Radiopharmaceuticals
  • Radiolabeled Reagents
  • Therapeutic Radiopharmaceuticals

Research Media Components & Growth Factor Alternatives Supply

Overview
Develops and manufactures growth factor alternative peptides for media, providing high-performance cell culture environments.
Competitiveness
High-activity peptide products based on proprietary technology.
Customers
  • Bio Research Institutions
  • Cell Culture Facilities
  • Pharmaceutical Development Departments
  • Cosmetics Manufacturers
Products
  • Growth Factor Alternative Peptides
  • Media Component Peptides
  • Culture Promoters

Drug Discovery & Pharmaceutical Joint R&D

Overview
Deploys a business model earning upfront payments and royalties through numerous partnership agreements with major global pharmaceuticals.
Competitiveness
Strengthened strategic collaborations with diverse partners.
Customers
  • AstraZeneca
  • Amgen
  • Daiichi Sankyo
  • Mitsubishi Tanabe Pharma
  • Novartis
  • GlaxoSmithKline
  • Bristol-Myers Squibb
  • Eli Lilly
  • Ipsen
  • Kyorin Pharmaceutical
  • Shionogi
Products
  • Joint Drug Discovery Projects
  • License Agreements
  • Milestone Payments
  • Royalties

R&D Collaboration

Overview
Leverages industry-academia collaboration to advance drug discovery platform technologies and explore new pharmaceutical targets.
Competitiveness
Strong academic collaboration foundation as a University of Tokyo spin-off.
Customers
  • Universities
  • Public Research Institutions
  • Venture Companies
Products
  • Joint Research Projects
  • Technology Evaluation
  • Research Funding Provision

Competitive Advantage

Strengths

  • Proprietary special peptide creation technology
  • Ownership of extensive patent portfolio
  • Strong partnerships with domestic and international pharmaceutical companies
  • Flexible drug discovery platform
  • Highly specialized R&D team
  • PDPS system combining diverse technologies
  • High library diversity and drug discovery speed
  • Stable production system via manufacturing JV
  • Business diversification through entry into radiopharmaceuticals
  • Academic collaborations unique to university spin-off

Competitive Advantages

  • Differentiation via proprietary peptide synthesis using special amino acids
  • Capable of constructing libraries of hundreds of billions of peptides in one test tube
  • Rapid R&D advancement through industry-academia-government collaboration
  • Risk diversification via close ties with diverse global pharma partners
  • Establishment of multifaceted revenue sources including radiopharmaceuticals
  • High-precision candidate selection via advanced screening technology
  • Prevention of technology leakage through comprehensive IP protection
  • Accountability in R&D focused on cancer and rare disease treatments
  • Enabling cutting-edge research through facility and environmental investments
  • Diverse bio-product lineup including growth factor alternative peptides

Threats

  • Complex and highly competitive pharmaceutical drug discovery market
  • Emergence of competitors from emerging technologies and bio-ventures
  • Prolongation of drug approval processes by regulatory authorities
  • Risk of contract termination due to partner company performance deterioration
  • Risk of patent infringement litigation in global markets
  • Profit pressure from escalating R&D costs
  • Impacts from domestic and international political-economic changes
  • Potential delays in research activities due to pandemics like COVID-19
  • Cybersecurity risks of technology leakage and know-how breaches
  • Stricter regulations on radiopharmaceutical manufacturing

Innovations

2024: New Radiopharmaceutical Manufacturing Line Construction

Overview
Introduced latest equipment to enhance PDR Pharma's production capacity and strengthen production system.
Impact
Achieved 20% increase in annual production volume and supply stabilization

2023: PDPS Technology Next-Gen Update

Overview
Integrated AI analysis into PDPS platform, significantly improving drug discovery efficiency.
Impact
Shortened drug candidate discovery period by 30%

2022: Peptistar Establishment for API Manufacturing Enhancement

Overview
Established special peptide API manufacturing JV with Shionogi and Sekisui Chemical.
Impact
20% cost reduction through in-house API supply

2021: Radiopharmaceutical Business Subsidiary Acquisition

Overview
Acquired radiopharmaceutical business from Fujifilm Toyama Chemical as subsidiary.
Impact
Advanced business diversification in diagnostics and therapeutics

2020: RAPID Display Technology Optimization

Overview
Implemented automation and accuracy improvements in screening processes.
Impact
15% improvement in search efficiency

Sustainability

  • Introduction and operation management of energy-efficient research facilities
  • Promotion of waste reduction and recycling rate improvements
  • Collaboration with local communities on environmental conservation
  • Thorough management of employee health and safety
  • Strengthened governance in supply chain
  • Implementation and periodic review of environmental impact assessments
  • Promotion of diversity and inclusion
  • Efforts to expand renewable energy usage